Yangmin Max Ning MD, PhD

Dr. Ning is a board-certified medical oncologist and serves as a senior reviewer in the Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, US Food and Drug Administration (FDA). He is also an active associate investigator, conducting clinical trials at the National Cancer Institute. He is interested in designing and evaluating clinical trials of novel cancer treatments, and is devoted to expediting patient access to important oncology products.  

He has evaluated hundreds of investigational oncology drug applications, reviewed 10 new oncology indication applications, and contributed to the design and monitoring of a number of key trials that led to recent regulatory approvals of new products for the treatment of prostate cancer. He has also received several awards, including the 2012 FDA Scientific Achievement Award for Excellence in Review Science.  His proactive review work for the successful development of vemurafenib and its companion diagnostic contributed to the genesis of the Breakthrough Therapy Designation program.

Dr. Ning trained in both basic and clinical science. He received his M.D. from Beijing Medical University and his Ph.D. from the Medical College of Ohio with research on steroid receptors’ signaling.  As a recipient of National Research Service Award, he had his post-doctoral training in genetic specificity regulation at the University of Michigan. He completed his residency in internal medicine at Wayne State University, followed by a clinical oncology-hematology fellowship at the National Cancer Institute and National Naval Medical Center. Based on his original research and review activities, he has authored book-chapters and well-cited publications (in JCO, JNCI, NEJM, CCR, JBC, PNAS, etc.), and has presented at national and international meetings.